Depot Medroxyprogesterone Acetate Subcutaneous Injection 104 mg/0.65 mL (DMPA-SC 104) is Associated With Fewer Hypoestrogenic Symptoms in Patients With Endometriosis Than Leuprolide Acetate

S.A. Carson, John K. Jain
In: Fertility and Sterility · 2005 · vol. 84 , pp. S191–S192 · doi:10.1016/j.fertnstert.2005.07.479 · W2148235720
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-21 ⓘ

Patients with endometriosis experienced fewer hypoestrogenic symptoms when treated with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL compared to leuprolide acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK